Impact of Anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) trial
We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI). The prognostic importance of anemia on primary PCI outcomes is unknown. In the Controlled Abciximab and Device Investigation to Lower Late Ang...
Gespeichert in:
| Veröffentlicht in: | Journal of the American College of Cardiology 2004-08, Vol.44 (3), p.547-553 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 553 |
|---|---|
| container_issue | 3 |
| container_start_page | 547 |
| container_title | Journal of the American College of Cardiology |
| container_volume | 44 |
| creator | NIKOLSKY, Eugenia AYMONG, Eve D STUCKEY, Thomas TURCO, Mark COHEN, David A NEGOITA, Manuela LANSKY, Alexandra J STONE, Gregg W HALKIN, Amir GRINES, Cindy L COX, David A GARCIA, Eulogio MEHRAN, Roxana TCHENG, James E GRIFFIN, John J GUAGLIUMI, Giulio |
| description | We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI).
The prognostic importance of anemia on primary PCI outcomes is unknown.
In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary PCI were randomized to balloon angioplasty versus stenting, each +/- abciximab. Outcomes were stratified by the presence of anemia at baseline, as defined by World Health Organization criteria (hematocrit |
| doi_str_mv | 10.1016/j.jacc.2004.03.080 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66868835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3242515301</sourcerecordid><originalsourceid>FETCH-LOGICAL-h299t-564d39662b8f8ed5619865ed8e6410f426532970e06af381f81ff6199ef936493</originalsourceid><addsrcrecordid>eNpdkV-LEzEUxQdR3Lr6BXyQC6LoQ2syadLEt6Hrn8KAL_pc0sxNmzKTjEmmaz-038HsbkUQEgKX3z3ncFJVLylZUELFh-PiqI1Z1IQsF4QtiCSPqhnlXM4ZV6vH1YysGJ9TolZX1bOUjoQQIal6Wl1RzrgkVM6q35th1CZDsNB4HJwG52HU2aHPCW5dPoA2U0YYzsHo2DndF8LqaLILHibfYdwH5_cwRjfoeIYRY1nQHsOUwIQY_N3U-YzxVETL1sdipftzcglsDAPkA8I6-BxD32MHzc64X0VrB9p3cIMnZxA2_oQpu72-t80B2nCLEVpdojV-78LY65TPxXAYe2fusQTv1s3Npm2b9XvIsUR_Xj2xuk_44vJeVz8-f_q-_jpvv33ZrJt2fqiVynMulh1TQtQ7aSV2XFAlBcdOolhSYpe14KxWK4JEaMskteXYAim0iomlYtfV2wfdMYafUwm-HVwy2PcPtWyFkEJKxgv4-j_wGKZY2klbyokoV8o76tWFmnYDdttL1du_31iANxdAJ6N7G7U3Lv3jBKWiZoT9AS0TsbE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1506150885</pqid></control><display><type>article</type><title>Impact of Anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>NIKOLSKY, Eugenia ; AYMONG, Eve D ; STUCKEY, Thomas ; TURCO, Mark ; COHEN, David A ; NEGOITA, Manuela ; LANSKY, Alexandra J ; STONE, Gregg W ; HALKIN, Amir ; GRINES, Cindy L ; COX, David A ; GARCIA, Eulogio ; MEHRAN, Roxana ; TCHENG, James E ; GRIFFIN, John J ; GUAGLIUMI, Giulio</creator><creatorcontrib>NIKOLSKY, Eugenia ; AYMONG, Eve D ; STUCKEY, Thomas ; TURCO, Mark ; COHEN, David A ; NEGOITA, Manuela ; LANSKY, Alexandra J ; STONE, Gregg W ; HALKIN, Amir ; GRINES, Cindy L ; COX, David A ; GARCIA, Eulogio ; MEHRAN, Roxana ; TCHENG, James E ; GRIFFIN, John J ; GUAGLIUMI, Giulio</creatorcontrib><description><![CDATA[We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI).
The prognostic importance of anemia on primary PCI outcomes is unknown.
In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary PCI were randomized to balloon angioplasty versus stenting, each +/- abciximab. Outcomes were stratified by the presence of anemia at baseline, as defined by World Health Organization criteria (hematocrit <39% for men and <36% for women).
Anemia was present in 260 (12.8%) of 2,027 randomized patients with baseline laboratory values. Patients with versus without baseline anemia more frequently developed in-hospital hemorrhagic complications (6.2% vs. 2.4%, p = 0.002), had higher rates of blood product transfusions (13.1% vs. 3.1%, p < 0.0001), and had a prolonged (median 4.1 vs. 3.5 days, p < 0.0001) and more expensive (median costs $12,434 vs. $11,603, p = 0.002) index hospitalization. Patients with versus without anemia had strikingly higher mortality during hospitalization (4.6% vs. 1.1%, p = 0.0003), at 30 days (5.8% vs. 1.5%, p < 0.0001), and at 1 year (9.4% vs. 3.5%, p < 0.0001). The rates of disabling stroke at 30 days (0.8% vs. 0.1%, p = 0.005) and at 1 year (2.1% vs. 0.4%, p = 0.0007) were also significantly higher in patients with anemia. By multivariate analysis, anemia was an independent predictor of in-hospital mortality (hazard ratio, 3.26; p = 0.048) and one-year mortality (hazard ratio, 2.38; p = 0.016).
Anemia at baseline in patients with AMI undergoing primary PCI is common, and is strongly associated with adverse outcomes and increased mortality.]]></description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2004.03.080</identifier><identifier>PMID: 15358018</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Science</publisher><subject>Aged ; Anemia ; Anemia - complications ; Anemias. Hemoglobinopathies ; Angioplasty ; Angioplasty, Balloon, Coronary - adverse effects ; Angioplasty, Balloon, Coronary - mortality ; Antibodies, Monoclonal - therapeutic use ; Aspirin ; Biological and medical sciences ; Blood Component Transfusion - statistics & numerical data ; Cardiology ; Cardiology. Vascular system ; Confidence intervals ; Coronary heart disease ; Diabetes ; Diseases of red blood cells ; Diseases of the cardiovascular system ; Female ; Heart ; Heart attacks ; Hematocrit ; Hematologic and hematopoietic diseases ; Hemorrhage - etiology ; Hemorrhage - prevention & control ; Hospital costs ; Hospital Mortality ; Hospitalization ; Humans ; Hypertension ; Immunoglobulin Fab Fragments - therapeutic use ; Incidence ; Ischemia ; Male ; Medical prognosis ; Medical sciences ; Middle Aged ; Mortality ; Multivariate Analysis ; Myocardial Infarction - complications ; Myocardial Infarction - mortality ; Myocardial Infarction - therapy ; Platelet Aggregation Inhibitors - therapeutic use ; Predictive Value of Tests ; Prognosis ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Randomized Controlled Trials as Topic ; Stents - adverse effects ; Stroke ; Stroke - etiology ; Stroke - prevention & control ; Survival Analysis ; Treatment Outcome ; Variables ; Veins & arteries ; Women</subject><ispartof>Journal of the American College of Cardiology, 2004-08, Vol.44 (3), p.547-553</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Aug 4, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16116230$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15358018$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NIKOLSKY, Eugenia</creatorcontrib><creatorcontrib>AYMONG, Eve D</creatorcontrib><creatorcontrib>STUCKEY, Thomas</creatorcontrib><creatorcontrib>TURCO, Mark</creatorcontrib><creatorcontrib>COHEN, David A</creatorcontrib><creatorcontrib>NEGOITA, Manuela</creatorcontrib><creatorcontrib>LANSKY, Alexandra J</creatorcontrib><creatorcontrib>STONE, Gregg W</creatorcontrib><creatorcontrib>HALKIN, Amir</creatorcontrib><creatorcontrib>GRINES, Cindy L</creatorcontrib><creatorcontrib>COX, David A</creatorcontrib><creatorcontrib>GARCIA, Eulogio</creatorcontrib><creatorcontrib>MEHRAN, Roxana</creatorcontrib><creatorcontrib>TCHENG, James E</creatorcontrib><creatorcontrib>GRIFFIN, John J</creatorcontrib><creatorcontrib>GUAGLIUMI, Giulio</creatorcontrib><title>Impact of Anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) trial</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description><![CDATA[We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI).
The prognostic importance of anemia on primary PCI outcomes is unknown.
In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary PCI were randomized to balloon angioplasty versus stenting, each +/- abciximab. Outcomes were stratified by the presence of anemia at baseline, as defined by World Health Organization criteria (hematocrit <39% for men and <36% for women).
Anemia was present in 260 (12.8%) of 2,027 randomized patients with baseline laboratory values. Patients with versus without baseline anemia more frequently developed in-hospital hemorrhagic complications (6.2% vs. 2.4%, p = 0.002), had higher rates of blood product transfusions (13.1% vs. 3.1%, p < 0.0001), and had a prolonged (median 4.1 vs. 3.5 days, p < 0.0001) and more expensive (median costs $12,434 vs. $11,603, p = 0.002) index hospitalization. Patients with versus without anemia had strikingly higher mortality during hospitalization (4.6% vs. 1.1%, p = 0.0003), at 30 days (5.8% vs. 1.5%, p < 0.0001), and at 1 year (9.4% vs. 3.5%, p < 0.0001). The rates of disabling stroke at 30 days (0.8% vs. 0.1%, p = 0.005) and at 1 year (2.1% vs. 0.4%, p = 0.0007) were also significantly higher in patients with anemia. By multivariate analysis, anemia was an independent predictor of in-hospital mortality (hazard ratio, 3.26; p = 0.048) and one-year mortality (hazard ratio, 2.38; p = 0.016).
Anemia at baseline in patients with AMI undergoing primary PCI is common, and is strongly associated with adverse outcomes and increased mortality.]]></description><subject>Aged</subject><subject>Anemia</subject><subject>Anemia - complications</subject><subject>Anemias. Hemoglobinopathies</subject><subject>Angioplasty</subject><subject>Angioplasty, Balloon, Coronary - adverse effects</subject><subject>Angioplasty, Balloon, Coronary - mortality</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Aspirin</subject><subject>Biological and medical sciences</subject><subject>Blood Component Transfusion - statistics & numerical data</subject><subject>Cardiology</subject><subject>Cardiology. Vascular system</subject><subject>Confidence intervals</subject><subject>Coronary heart disease</subject><subject>Diabetes</subject><subject>Diseases of red blood cells</subject><subject>Diseases of the cardiovascular system</subject><subject>Female</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Hematocrit</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemorrhage - etiology</subject><subject>Hemorrhage - prevention & control</subject><subject>Hospital costs</subject><subject>Hospital Mortality</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Immunoglobulin Fab Fragments - therapeutic use</subject><subject>Incidence</subject><subject>Ischemia</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate Analysis</subject><subject>Myocardial Infarction - complications</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - therapy</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Stents - adverse effects</subject><subject>Stroke</subject><subject>Stroke - etiology</subject><subject>Stroke - prevention & control</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Variables</subject><subject>Veins & arteries</subject><subject>Women</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkV-LEzEUxQdR3Lr6BXyQC6LoQ2syadLEt6Hrn8KAL_pc0sxNmzKTjEmmaz-038HsbkUQEgKX3z3ncFJVLylZUELFh-PiqI1Z1IQsF4QtiCSPqhnlXM4ZV6vH1YysGJ9TolZX1bOUjoQQIal6Wl1RzrgkVM6q35th1CZDsNB4HJwG52HU2aHPCW5dPoA2U0YYzsHo2DndF8LqaLILHibfYdwH5_cwRjfoeIYRY1nQHsOUwIQY_N3U-YzxVETL1sdipftzcglsDAPkA8I6-BxD32MHzc64X0VrB9p3cIMnZxA2_oQpu72-t80B2nCLEVpdojV-78LY65TPxXAYe2fusQTv1s3Npm2b9XvIsUR_Xj2xuk_44vJeVz8-f_q-_jpvv33ZrJt2fqiVynMulh1TQtQ7aSV2XFAlBcdOolhSYpe14KxWK4JEaMskteXYAim0iomlYtfV2wfdMYafUwm-HVwy2PcPtWyFkEJKxgv4-j_wGKZY2klbyokoV8o76tWFmnYDdttL1du_31iANxdAJ6N7G7U3Lv3jBKWiZoT9AS0TsbE</recordid><startdate>20040804</startdate><enddate>20040804</enddate><creator>NIKOLSKY, Eugenia</creator><creator>AYMONG, Eve D</creator><creator>STUCKEY, Thomas</creator><creator>TURCO, Mark</creator><creator>COHEN, David A</creator><creator>NEGOITA, Manuela</creator><creator>LANSKY, Alexandra J</creator><creator>STONE, Gregg W</creator><creator>HALKIN, Amir</creator><creator>GRINES, Cindy L</creator><creator>COX, David A</creator><creator>GARCIA, Eulogio</creator><creator>MEHRAN, Roxana</creator><creator>TCHENG, James E</creator><creator>GRIFFIN, John J</creator><creator>GUAGLIUMI, Giulio</creator><general>Elsevier Science</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20040804</creationdate><title>Impact of Anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) trial</title><author>NIKOLSKY, Eugenia ; AYMONG, Eve D ; STUCKEY, Thomas ; TURCO, Mark ; COHEN, David A ; NEGOITA, Manuela ; LANSKY, Alexandra J ; STONE, Gregg W ; HALKIN, Amir ; GRINES, Cindy L ; COX, David A ; GARCIA, Eulogio ; MEHRAN, Roxana ; TCHENG, James E ; GRIFFIN, John J ; GUAGLIUMI, Giulio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h299t-564d39662b8f8ed5619865ed8e6410f426532970e06af381f81ff6199ef936493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Anemia</topic><topic>Anemia - complications</topic><topic>Anemias. Hemoglobinopathies</topic><topic>Angioplasty</topic><topic>Angioplasty, Balloon, Coronary - adverse effects</topic><topic>Angioplasty, Balloon, Coronary - mortality</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Aspirin</topic><topic>Biological and medical sciences</topic><topic>Blood Component Transfusion - statistics & numerical data</topic><topic>Cardiology</topic><topic>Cardiology. Vascular system</topic><topic>Confidence intervals</topic><topic>Coronary heart disease</topic><topic>Diabetes</topic><topic>Diseases of red blood cells</topic><topic>Diseases of the cardiovascular system</topic><topic>Female</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Hematocrit</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemorrhage - etiology</topic><topic>Hemorrhage - prevention & control</topic><topic>Hospital costs</topic><topic>Hospital Mortality</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Immunoglobulin Fab Fragments - therapeutic use</topic><topic>Incidence</topic><topic>Ischemia</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate Analysis</topic><topic>Myocardial Infarction - complications</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - therapy</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Stents - adverse effects</topic><topic>Stroke</topic><topic>Stroke - etiology</topic><topic>Stroke - prevention & control</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Variables</topic><topic>Veins & arteries</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>NIKOLSKY, Eugenia</creatorcontrib><creatorcontrib>AYMONG, Eve D</creatorcontrib><creatorcontrib>STUCKEY, Thomas</creatorcontrib><creatorcontrib>TURCO, Mark</creatorcontrib><creatorcontrib>COHEN, David A</creatorcontrib><creatorcontrib>NEGOITA, Manuela</creatorcontrib><creatorcontrib>LANSKY, Alexandra J</creatorcontrib><creatorcontrib>STONE, Gregg W</creatorcontrib><creatorcontrib>HALKIN, Amir</creatorcontrib><creatorcontrib>GRINES, Cindy L</creatorcontrib><creatorcontrib>COX, David A</creatorcontrib><creatorcontrib>GARCIA, Eulogio</creatorcontrib><creatorcontrib>MEHRAN, Roxana</creatorcontrib><creatorcontrib>TCHENG, James E</creatorcontrib><creatorcontrib>GRIFFIN, John J</creatorcontrib><creatorcontrib>GUAGLIUMI, Giulio</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NIKOLSKY, Eugenia</au><au>AYMONG, Eve D</au><au>STUCKEY, Thomas</au><au>TURCO, Mark</au><au>COHEN, David A</au><au>NEGOITA, Manuela</au><au>LANSKY, Alexandra J</au><au>STONE, Gregg W</au><au>HALKIN, Amir</au><au>GRINES, Cindy L</au><au>COX, David A</au><au>GARCIA, Eulogio</au><au>MEHRAN, Roxana</au><au>TCHENG, James E</au><au>GRIFFIN, John J</au><au>GUAGLIUMI, Giulio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) trial</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>2004-08-04</date><risdate>2004</risdate><volume>44</volume><issue>3</issue><spage>547</spage><epage>553</epage><pages>547-553</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract><![CDATA[We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI).
The prognostic importance of anemia on primary PCI outcomes is unknown.
In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary PCI were randomized to balloon angioplasty versus stenting, each +/- abciximab. Outcomes were stratified by the presence of anemia at baseline, as defined by World Health Organization criteria (hematocrit <39% for men and <36% for women).
Anemia was present in 260 (12.8%) of 2,027 randomized patients with baseline laboratory values. Patients with versus without baseline anemia more frequently developed in-hospital hemorrhagic complications (6.2% vs. 2.4%, p = 0.002), had higher rates of blood product transfusions (13.1% vs. 3.1%, p < 0.0001), and had a prolonged (median 4.1 vs. 3.5 days, p < 0.0001) and more expensive (median costs $12,434 vs. $11,603, p = 0.002) index hospitalization. Patients with versus without anemia had strikingly higher mortality during hospitalization (4.6% vs. 1.1%, p = 0.0003), at 30 days (5.8% vs. 1.5%, p < 0.0001), and at 1 year (9.4% vs. 3.5%, p < 0.0001). The rates of disabling stroke at 30 days (0.8% vs. 0.1%, p = 0.005) and at 1 year (2.1% vs. 0.4%, p = 0.0007) were also significantly higher in patients with anemia. By multivariate analysis, anemia was an independent predictor of in-hospital mortality (hazard ratio, 3.26; p = 0.048) and one-year mortality (hazard ratio, 2.38; p = 0.016).
Anemia at baseline in patients with AMI undergoing primary PCI is common, and is strongly associated with adverse outcomes and increased mortality.]]></abstract><cop>New York, NY</cop><pub>Elsevier Science</pub><pmid>15358018</pmid><doi>10.1016/j.jacc.2004.03.080</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-1097 |
| ispartof | Journal of the American College of Cardiology, 2004-08, Vol.44 (3), p.547-553 |
| issn | 0735-1097 1558-3597 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66868835 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Aged Anemia Anemia - complications Anemias. Hemoglobinopathies Angioplasty Angioplasty, Balloon, Coronary - adverse effects Angioplasty, Balloon, Coronary - mortality Antibodies, Monoclonal - therapeutic use Aspirin Biological and medical sciences Blood Component Transfusion - statistics & numerical data Cardiology Cardiology. Vascular system Confidence intervals Coronary heart disease Diabetes Diseases of red blood cells Diseases of the cardiovascular system Female Heart Heart attacks Hematocrit Hematologic and hematopoietic diseases Hemorrhage - etiology Hemorrhage - prevention & control Hospital costs Hospital Mortality Hospitalization Humans Hypertension Immunoglobulin Fab Fragments - therapeutic use Incidence Ischemia Male Medical prognosis Medical sciences Middle Aged Mortality Multivariate Analysis Myocardial Infarction - complications Myocardial Infarction - mortality Myocardial Infarction - therapy Platelet Aggregation Inhibitors - therapeutic use Predictive Value of Tests Prognosis Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Randomized Controlled Trials as Topic Stents - adverse effects Stroke Stroke - etiology Stroke - prevention & control Survival Analysis Treatment Outcome Variables Veins & arteries Women |
| title | Impact of Anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty complications (CADILLAC) trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T18%3A15%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Anemia%20in%20patients%20with%20acute%20myocardial%20infarction%20undergoing%20primary%20percutaneous%20coronary%20intervention:%20Analysis%20from%20the%20Controlled%20Abciximab%20and%20Device%20Investigation%20to%20Lower%20Late%20Angioplasty%20complications%20(CADILLAC)%20trial&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=NIKOLSKY,%20Eugenia&rft.date=2004-08-04&rft.volume=44&rft.issue=3&rft.spage=547&rft.epage=553&rft.pages=547-553&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/j.jacc.2004.03.080&rft_dat=%3Cproquest_pubme%3E3242515301%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1506150885&rft_id=info:pmid/15358018&rfr_iscdi=true |